Epizyme Inc. had hoped its real-world natural history study would convince the agency that the benefit clinical trial participants experienced with Tazverik (tazemetostat) was greater than what epithelioid sarcoma patients see with standard of care.
However, the real-world study, which was based on retrospective chart review, did not factor into the FDA’s efficacy assessment of...